Fitbit
BehavioralParticipants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
NCT Number: NCT02700243
In this research study the investigators want to learn more about whether using a fitness tracker and accelerometer helps patients with cystic fibrosis exercise more regularly, and in turn whether it increases exercise tolerance over the period of one year.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
The aim of this study is to evaluate whether the use of a Fitbit device and an exercise prescription is associated with increased daily activity and in turn increased exercise tolerance in young adult patients with cystic fibrosis (CF). The investigators hypothesize that use of the Fitbit and an exercise prescription will be associated with increased exercise tolerance compared to standard counseling and an exercise prescription alone.
For patients with CF, young adulthood and adolescence is a significant time of vulnerability. In addition to normal behavioral challenges of adolescence and young adulthood (seeking independence/autonomy while also choosing rebellion), those with CF are often dealing with significant disease progression. Therefore, working in new innovative ways to improve adherence to regimens that improve lung function such as exercise are needed to continue to support patients during this vulnerable time.
Studies of patients with cystic fibrosis have shown that regular exercise training can decrease rate of lung function decline, potentially improve lung function, and improve aerobic capacity. However, many patients do not include regular exercise in their daily routine. Successful strategies to improve adherence include providing patient specific guidelines for an appropriate exercise program, supporting participation and providing positive feedback. Overall, exercise is a crucial diagnostic and therapeutic modality for patients with Cystic Fibrosis, although awareness somewhat limited. The adult CF program at Boston Children's and Brigham & Women's Hospital established an inpatient and outpatient exercise program as part of a quality improvement effort. Patients are prescribed an individualized exercise program or exercise prescription based on their assessment during a sub-maximal effort. This program has been successful but given the rigors of daily life (e.g. school, work, family obligations), adherence is a concern with resources limiting more rigorous feedback to maintain this essential life activity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
Time frame: Two years (Enrollment, 6 months, 12 months, 24 months)
Change is submaximal GXT will be assessed for all participants
Time frame: Two years
Time frame: Two years
Time frame: Two years
Forced Expiratory Volume in one second (FEV1) from before study (Baseline) to each data collection timepoint, and from one data collection timepoint to the next.
Time frame: Two years
Forced Vital Capacity in one second (FVC) from before study (Baseline) to each data collection timepoint, and from one data collection timepoint to the next.
Time frame: Two years
Forced Expiratory Flow in one second (FEF25-75) from before study (Baseline) to each data collection timepoint, and from one data collection timepoint to the next.
Time frame: Two years
Time frame: Two years
Time frame: Two years
Time frame: Two years (6 Month Time Point)
Qualitative data obtained by open-ended interview
Time frame: Two years (6 Month Time Point)
Qualitative data obtained by open-ended interview
Time frame: Two years (6 Month Time Point)
Qualitative data obtained by open-ended interview
Time frame: Two years (Enrollment, 6 months, 12 months, 18 months, 24 months)
Depression scale scored 0-27, with a score of 0-4 indicating minimal risk for depression/anxiety, a score of 5-9 indicating mild risk for depression/anxiety, a score of 10-14 indicating moderate risk for depression/anxiety, and a score if 15-27 indicating severe risk for depression/anxiety.
Time frame: Two years (Enrollment, 6 months, 12 months, 18 months, 24 months)
Depression scale scored 0-21, with a score of 0-4 indicating minimal risk for depression/anxiety, a score of 5-9 indicating mild risk for depression/anxiety, a score of 10-14 indicating moderate risk for depression/anxiety, and a score if 15-21 indicating severe risk for depression/anxiety.
Boston Children's Hospital
Other
Pilot RCT Study Using a Fitbit Device to Improve Exercise Tolerance in 80 Patients With Cystic Fibrosis
Acronym: INTERACT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01848392
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Paris, France
View Trial DetailsNCT05590169
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05147285
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ankara, Turkey (Türkiye)
View Trial DetailsNCT04888767
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Roscoff, Finistère, France
View Trial Details